Newton Peters, MD
Ophthalmology · Portsmouth, NHNPI 1407859556
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,020 of the $4,996 with a category attached, or 60.4%. 19 manufacturers reported payments, led by Glaukos Corporation at 47.6% of the total. 2025 is the largest year on record at $2,818, more than ten times the $282 reported in 2019.
Across 97 payments — averaging $51.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Harrow Eye, LLC$583
- Ocular Therapeutix, Inc.$377
- Alcon$375
- Rxsight Inc$305
- AbbVie$282
- plus $696 from 13 others
Across 13 payments — averaging $15,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$204K
- Bausch & Lomb Americas Inc.$750
What the payments were for
- Consulting fees$1,79736%
- Speaking & faculty fees$391%
- Food & beverage$3,02060%
- Other$1403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 9 | $2,377 |
| Harrow Eye, LLC | 7 | $583 |
| Ocular Therapeutix, Inc. | 16 | $377 |
| Alcon | 18 | $375 |
| Rxsight Inc | 3 | $305 |
| AbbVie(2 entities) | 13 | $282 |
| Aerie Pharmaceuticals, Inc. | 7 | $135 |
| Dompe US, Inc. | 2 | $121 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $102 |
| Amgen | 4 | $67 |
| Rayner Intraocular Lenses Limited | 2 | $46 |
| Sight Sciences, Inc. | 3 | $42 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Tarsus Pharmaceuticals, Inc. | 1 | $37 |
| Digital Diagnostics Inc. | 1 | $30 |
| Novartis | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,996 in reported general payments places this provider in the 80th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 85 | $3,629 |
| MoxifloxacinMoxifloxacin Hcl | 43 | $1,308 |
| Ketorolac Tromethamine | 29 | $1,122 |
| Latanoprost | 63 | $599 |
| Timolol Maleate | 23 | $423 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Portsmouth
- Jason SzelogPortsmouth$71K
- Jennifer LingPortsmouth$9K
- Claudia BartoliniPortsmouth$4K
- Warren GoldblattPortsmouth$3K
- Timothy SullivanPortsmouth$3K
- Lucian SzmydPortsmouth$2K
- Richard LasondePortsmouth$1K
- Nathaniel SearsPortsmouth$601
- Marsha KavanaghPortsmouth$371
- Dane SlentzDerry$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.